Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mechanical unloading aggravates bone destruction and tumor expansion in myeloma.
Tanimoto K, Hiasa M, Tenshin H, Teramachi J, Oda A, Harada T, Higa Y, Sogabe K, Oura M, Sumitani R, Hara T, Endo I, Matsumoto T, Tanaka E, Abe M. Tanimoto K, et al. Among authors: sogabe k. Haematologica. 2022 Mar 1;107(3):744-749. doi: 10.3324/haematol.2021.278295. Haematologica. 2022. PMID: 34788982 Free PMC article. No abstract available.
TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma.
Teramachi J, Tenshin H, Hiasa M, Oda A, Bat-Erdene A, Harada T, Nakamura S, Ashtar M, Shimizu S, Iwasa M, Sogabe K, Oura M, Fujii S, Kagawa K, Miki H, Endo I, Haneji T, Matsumoto T, Abe M. Teramachi J, et al. Among authors: sogabe k. Haematologica. 2021 May 1;106(5):1401-1413. doi: 10.3324/haematol.2019.234476. Haematologica. 2021. PMID: 32273474 Free PMC article.
Reveromycin A, a novel acid-seeking agent, ameliorates bone destruction and tumor growth in multiple myeloma.
Watanabe K, Bat-Erdene A, Tenshin H, Cui Q, Teramachi J, Hiasa M, Oda A, Harada T, Miki H, Sogabe K, Oura M, Sumitani R, Mitsui Y, Endo I, Tanaka E, Kawatani M, Osada H, Matsumoto T, Abe M. Watanabe K, et al. Among authors: sogabe k. Haematologica. 2021 Apr 1;106(4):1172-1177. doi: 10.3324/haematol.2019.244418. Haematologica. 2021. PMID: 32586903 Free PMC article. No abstract available.
Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors.
Bat-Erdene A, Miki H, Oda A, Nakamura S, Teramachi J, Amachi R, Tenshin H, Hiasa M, Iwasa M, Harada T, Fujii S, Sogabe K, Kagawa K, Yoshida S, Endo I, Aihara K, Abe M. Bat-Erdene A, et al. Among authors: sogabe k. Oncotarget. 2016 Nov 29;7(48):79064-79075. doi: 10.18632/oncotarget.12594. Oncotarget. 2016. PMID: 27738323 Free PMC article.
Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA.
Bat-Erdene A, Nakamura S, Oda A, Iwasa M, Teramachi J, Ashtar M, Harada T, Miki H, Tenshin H, Hiasa M, Fujii S, Sogabe K, Oura M, Udaka K, Kagawa K, Yoshida S, Aihara KI, Kurahashi K, Endo I, Abe M. Bat-Erdene A, et al. Among authors: sogabe k. Br J Haematol. 2019 Jun;185(5):969-974. doi: 10.1111/bjh.15673. Epub 2018 Nov 26. Br J Haematol. 2019. PMID: 30474853 Free article. No abstract available.
Correlation between high serum alkaline phosphatase levels and denosumab-related hypocalcemia in patients with multiple myeloma.
Miki H, Nakamura S, Oura M, Hamano H, Ikuta K, Okada N, Okamoto Y, Sogabe K, Takahashi M, Iwasa M, Udaka K, Harada T, Kurahashi K, Fujii S, Yoshida S, Kagawa K, Endo I, Aihara KI, Abe M. Miki H, et al. Among authors: sogabe k. Br J Haematol. 2019 Jul;186(2):355-358. doi: 10.1111/bjh.15837. Epub 2019 Mar 11. Br J Haematol. 2019. PMID: 30859556 Free article. Clinical Trial. No abstract available.
TGF-β-activated kinase-1 inhibitor LL-Z1640-2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF-α and RANKL expression.
Tenshin H, Teramachi J, Ashtar M, Hiasa M, Inoue Y, Oda A, Tanimoto K, Shimizu S, Higa Y, Harada T, Oura M, Sogabe K, Hara T, Sumitani R, Maruhashi T, Sebe M, Tsutsumi R, Sakaue H, Endo I, Matsumoto T, Tanaka E, Abe M. Tenshin H, et al. Among authors: sogabe k. Clin Transl Immunology. 2022 Jan 19;11(1):e1371. doi: 10.1002/cti2.1371. eCollection 2022. Clin Transl Immunology. 2022. PMID: 35079379 Free PMC article.
Expansion of Th1-like Vγ9Vδ2T cells by new-generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acid.
Harada T, Miki H, Cui Q, Oda A, Amachi R, Teramachi J, Bat-Erdene A, Sogabe K, Iwasa M, Fujii S, Nakamura S, Kagawa K, Yoshida S, Endo I, Aihara K, Ozaki S, Matsumoto T, Abe M. Harada T, et al. Among authors: sogabe k. Leukemia. 2017 Jan;31(1):258-262. doi: 10.1038/leu.2016.273. Epub 2016 Oct 4. Leukemia. 2017. PMID: 27698446 No abstract available.
TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects.
Tenshin H, Teramachi J, Oda A, Amachi R, Hiasa M, Bat-Erdene A, Watanabe K, Iwasa M, Harada T, Fujii S, Kagawa K, Sogabe K, Nakamura S, Miki H, Kurahashi K, Yoshida S, Aihara K, Endo I, Tanaka E, Matsumoto T, Abe M. Tenshin H, et al. Among authors: sogabe k. Blood Adv. 2017 Oct 26;1(24):2124-2137. doi: 10.1182/bloodadvances.2017008813. eCollection 2017 Nov 14. Blood Adv. 2017. PMID: 29296860 Free PMC article.
PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ.
Iwasa M, Harada T, Oda A, Bat-Erdene A, Teramachi J, Tenshin H, Ashtar M, Oura M, Sogabe K, Udaka K, Fujii S, Nakamura S, Miki H, Kagawa K, Ozaki S, Abe M. Iwasa M, et al. Among authors: sogabe k. Oncotarget. 2019 Mar 8;10(20):1903-1917. doi: 10.18632/oncotarget.26726. eCollection 2019 Mar 8. Oncotarget. 2019. PMID: 30956773 Free PMC article.
117 results